Compare Amgen, Inc. (AMGN) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Tidewater Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Tidewater Inc trades at $74.37 (market cap $3.65B). The key difference: Amgen, Inc. is far larger — about 53.7× Tidewater Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| AMGN | TDW | |
|---|---|---|
Market Cap | $196.12B | $3.65B |
Sector | Health | Utilities |
52-Week High | $388.16 | $91.12 |
52-Week Low | $271.18 | $46.32 |
Enterprise Value | $241.41B | $3.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Tidewater (TDW) trades at $73.37, up 3.84% with bullish technical signals from moving averages. The company maintains strong profitability with 22.16% net income margin and 24.03% ROE, though recent Q1 2026 earnings missed estimates. Valuation appears reasonable with P/E of 12.37 and EV/EBITDA of 9.15. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics and mixed analyst sentiment.
The outlook remains cautiously optimistic given strong fundamentals but tempered by recent earnings misses. Investment opportunity lies in reasonable valuation and sector positioning, while risks include execution challenges and energy market volatility. Analyst consensus leans neutral with 61.54% hold ratings, suggesting balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
